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Abstract
Background: Acute promyelocytic leukemia (APL) is associated with chromosomal translocation t(15;17), which
results in the proliferation of morphologically abnormal promyelocytes. Gain of supernumerary copies of the 8q24
chromosomal region, which harbors MYC and PVT1, has been shown to be the most common secondary alteration
in human APL. Increased MYC can accelerate the development of myeloid leukemia in APL. However, the role that
the expression of the long non-coding RNA (lncRNA) PVT1 plays in the pathogenesis of APL remains largely unknown.
Findings: In this study, we first analyzed the lncRNA PVT1 expression level in peripheral blood cells from 28 patients
with de novo APL, and significantly upregulated PVT1 was found in APL patients compared with healthy donors. We
then observed significantly lower MYC and PVT1 expression during all-trans retinoic acid (ATRA)-induced differentiation
and cell cycle arrest in the APL cell line. MYC knockdown in NB4 cells led to PVT1 downregulation. Moreover, PVT1
knockdown by RNA interference led to suppression of the MYC protein level, and cell proliferation was inhibited.
Conclusion: Our findings reveal that the lncRNA PVT1 may play an important role in the proliferation of APL cells and
may be useful for future therapeutic management.
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Background
Acute promyelocytic leukemia (APL) is characterized by
a balanced reciprocal translocation between chromo-
somes 15 and 17, which leads to the expression of the
fusion protein PML-RARα [1, 2]. All-trans retinoic acid
(ATRA) and arsenic trioxide (ATO) have been used in
APL therapy to induce the degradation of the key
leukemogenic protein PML-RARα [3, 4]. Transcription
factors such as PU.1 are involved in the pathogenesis of
APL [3, 5, 6]. However, the precise mechanisms involved
in APL pathogenesis beyond genetic alterations remain
poorly understood [7].
Non-coding RNAs, such as microRNAs (miRNAs) and
long non-coding RNAs (lncRNAs), have been implicated in
the carcinogenesis of many different cancer types [8–11].
LncRNAs are non-protein coding transcripts longer than
200 nucleotides, and they account for a large proportion of
the mammalian genome [12]. Recently, it has been sug-
gested that lncRNAs are crucial for the development of ma-
lignant tumors [13–15]. LncRNAs have been demonstrated
to regulate gene expression through epigenetic, transcrip-
tional, and posttranscriptional regulation, and they are in-
volved in X chromosome silencing, genomic imprinting,
chromatin modifications, and other important regulatory
processes [14, 16–21]. For example, a recent study has indi-
cated that HOTAIRM1 (HOX transcript antisense RNA)
provides a regulatory link in myeloid maturation by modu-
lating integrin-controlled cell cycle progression at the gene
expression level [22]. We previously demonstrated that
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lncRNAs play a significant role in regulating differentiation
in APL cells [13].
PML-RARα is an initiating factor for APL
leukemogenesis [23–26]. However, leukemia development
in transgenic mice expressing PML-RARα occurs after a
long latency period [27], which strongly suggests that
PML-RARα collaborates with additional genetic lesions to
block differentiation and promote leukemia. In fact, gain
of supernumerary copies of the 8q24 chromosomal region
has been shown to be the most common secondary alter-
ation in human APL [28]. The lncRNA PVT1 is located
on chromosome 8q24, a location shared with the well-
known oncogene c-myc [29, 30]. Chromosome 8q24 has
an equivalent in mice (chromosome 15), which is the most
commonly recurring abnormality in PML-RARα trans-
genic mice [28], and it cooperates with PML-RARα to
accelerate the development of myeloid leukemia [31].
Previous studies have focused on the c-myc oncogene,
and it remains unknown whether the lncRNA PVT1
in the same region is also involved in leukemia. In
this study, we aimed to characterize the role and
regulation of PVT1 in APL.
Results
PVT1 is upregulated in APL
To investigate whether PVT1 is involved in the devel-
opment of APL, we initially compared the PVT1 ex-
pression in primary APL patient samples with that in
healthy donors. As shown in Fig. 1, the PVT1 expres-
sion level was significantly elevated in APL samples
compared with healthy donors. This result suggests
that PVT1 upregulation may be associated with the
pathogenesis of APL cells.
ATRA treatment represses PVT1 expression
Because ATRA treatment leads to a proliferation block
and the differentiation of leukemia blasts, we next inves-
tigated PVT1 expression in the APL cell line NB4 before
and after ATRA treatment (1 μM). Using qRT-PCR, the
PVT1 expression level in NB4 cells was downregulated
upon treatment with ATRA (Fig. 2a). There was no
PVT1 downregulation in an ATRA-resistant cell line
(NB4-R2) upon ATRA treatment, excluding a non-
specific stress response to ATRA treatment (Additional
file 1: Figure S1). Because it was reported that the well-
known protein MYC is a PVT1 transcriptional activator,
we further investigated the effects of ATRA on c-myc
expression. Consistent with previous studies [32], treat-
ment of APL cells with ATRA inhibited the expression
of c-myc messenger RNA (mRNA) (Fig. 2b). Because of
the remarkable association between PVT1 expression
and MYC revealed by this study and others, we further
investigated the effects of MYC on PVT1 expression. As
shown in Fig. 2c, knockdown of MYC in NB4 cells led
to PVT1 downregulation. These data suggest that PVT1
may be regulated by MYC and is involved in the prolif-
eration of APL cells.
Knockdown of PVT1 impairs the proliferation of APL cells
Based on the above data, we further elucidated the func-
tion of PVT1 during proliferation using CCK-8 assays.
Reduced PVT1 expression in cells transfected with
PVT1-specific small interfering RNA (siRNA) was con-
firmed by qRT-PCR (Fig. 3a). As shown in Fig. 3b, cells
transfected si-PVT1 had a lower survival rate than those
in the control group. In an effort to determine whether
PVT1 is involved in regulating the oncoprotein MYC,
we examined the MYC expression level in cells transfected
si-PVT1. PVT1 knockdown had no effect on c-myc RNA
but led to the suppression of the MYC protein level in
NB4 cells (Fig. 3c). These results suggest that the PVT1
lncRNA is involved in abnormal APL cell proliferation.
Discussion
Leukemia is a hematologic disease in which cells are
blocked at a certain stage of hematopoietic differenti-
ation and display a high proliferative capacity [7, 33]. Re-
cently, increasing evidence has suggested that lncRNAs
are involved in fundamental biological processes, such as
cell proliferation, survival, and differentiation [14, 18]. In
this study, we reveal for the first time that the lncRNA
PVT1 is significantly upregulated in primary APL
cells. Additionally, we provide evidence that upregu-
lated PVT1 expression is involved in the proliferation
of APL cells.
More recently, the lncRNA PVT1 has been shown to
be dysregulated in several cancers, and it has been func-
tionally linked to cancer tumorigenesis [34–37]. PVT1 is
Fig. 1 The lncRNA PVT1 is significantly upregulated in APL patient
samples. Comparison of PVT1 expression in granulocytes from healthy
donors (normal, n = 12) compared with APL cells (n = 28). PVT1
expression was detected by qRT-PCR and normalized to the ACTB
gene. The expression of PVT1 relative to that in healthy samples was
calculated using the 2−DeltaDeltaCt method. P values between samples
were obtained by performing a t test. *** p < 0.001
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an lncRNA (1.9 kb) and host gene for several miRNAs
[38]. Although there are a few reports demonstrating
that PVT1 plays an important role in the pathogenesis
of several cancers, it is not yet clear whether PVT1 is in-
volved in the regulation of APL, which is a unique sub-
type of acute myeloid leukemia (AML) that results from
a blockade in granulocyte differentiation during the pro-
myelocytic stage. Here, we found that PVT1 expression
is elevated in APL, and its expression is repressed during
ATRA-induced differentiation and cell cycle arrest. c-
myc and PVT1 were located on chromosome 8q24; gain
of supernumerary copies of the 8q24 chromosomal re-
gion in human APL may led to increased copy number
of PVT1 in APL. In addition to a gain in 8q24, the well-
known MYC protein is a transcriptional activator of
PVT1 [32] and increased in human APL [31], and it has
been reported that treating APL cells with ATRA
inhibits the expression of c-myc mRNA [39], suggesting
that elevated PVT1 expression may also result from
MYC protein activation in APL cells. Similarly, in our
study, c-myc knockdown led to PVT1 downregulation.
Interestingly, PVT1 inhibition could attenuate the prolif-
eration of APL cells, indicating that PVT1 is essential
for APL progression. A recent study has found that
PVT1 increases NOP2 levels by enhancing the stability
of the NOP2 protein in hepatocellular carcinoma and
that the function of PVT1 in cell proliferation is
dependent on the presence of NOP2 [34]. More import-
antly, a recent report has also highlighted the involve-
ment of PVT1 in regulating MYC, which has been
firmly established to play a role in cancer [40]. Indeed,
we confirmed that PVT1 depletion causes a reduction in
the MYC protein level in APL. Thus, PVT1 may influ-
ence the stability of these important proteins, which are
Fig. 2 PVT1 was significantly decreased in NB4 cells treated with ATRA. a NB4 cells were treated with 1 μM ATRA. PVT1 was measured by qRT-PCR and
normalized to the house keeping gene ACTB. b The level of c-myc mRNA in NB4 cells treated with ATRA was detected by qPCR. ATRA
treatment demonstrated broadly similar effects on MYC and PVT1 expression. Each panel shows the mean ± SD of a representative experiment
performed in triplicate. c qRT-PCR analysis of MYC and PVT1 in APL cells after MYC knockdown
Fig. 3 PVT1 inhibition attenuates the proliferation of APL cells. The PVT1 expression level was detected in NB4 cells transfected with siRNA specifically
targeting PVT1 (si-PVT1) or negative control siRNA (si-NC). a qRT-PCR analysis showed that the PVT1 expression level in cells transfected with si-PVT1
was significantly lower than that in cells transfected with si-NC. b PVT1 knockdown impaired the growth of APL Cells. The data are the result of three
independent experiments and are presented as means ± SD. c qRT-PCR and Western blot analysis of MYC in APL cells after siRNA transfection
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indispensable for APL cell growth. It is therefore pos-
sible that PVT1 could be a novel biomarker for APL
diagnosis, prognosis, and targeted therapy [41].
In conclusion, we demonstrated that abnormal ele-
vated expression of the lncRNA PVT1 may be correlated
with APL cell proliferation. This is, to our knowledge,
the first report of a potential role for the lncRNA PVT1
in APL. These findings provide new insight into the
mechanism of APL progression.
Materials and methods
Samples
A total of 40 peripheral blood samples including 28 APL
samples taken from the time of diagnosis and 12 sam-
ples from healthy donors were included in this study.
The patient characteristics are summarized in Table 1.
The peripheral blood mononuclear cells (PBMCs) of
APL samples were isolated using Ficoll–Hypaque gradi-
ent centrifugation method [42, 43]. Granulocytes from
healthy donors were isolated as previous studies [44]. All
of the procedures were conducted according to the
guidelines of the Medical Ethics Committee of the
Health Bureau of the Guangdong Province of China.
This study was approved by the Ethics Committee of the
Medical School of Jinan University.
Cell lines and cell cultures
The NB4 and NB4-R2 cell lines were kindly provided by
Dr. Yueqin Chen (Sun Yat-sen University, Guangzhou,
China) and cultured in RPMI 1640 (HyClone, SH30027)
containing 10 % fetal bovine serum (HyClone, SV30160)
at 37 °C in a 5 % CO2 incubator. ATRA was purchased
from Sigma-Aldrich and used at a final concentration of
1 μM (Sigma-Aldrich, R2625; stock: 10 mM in EtOH).
RNA extraction and qRT-PCR analysis
Total RNA was extracted with TRIzol reagent (Invitrogen)
according to the manufacturer’s protocol. RNA was re-
verse transcribed into cDNA using a Reverse Transcrip-
tion Kit (Takara, Japan). Real-time PCR was performed
with SYBR Green (TIANGEN, China). ACTB was used as
a reference for both mRNA and lncRNA, and each sample









c-myc siRNA (CGAUGUUGUUUCUGUGGAA) [46],
PVT1 siRNA (PVT-1 siRNA-1: GCUUGGAGGCUGAG
GAGUUTT and PVT-1 siRNA-2: CCCAACAGGAGG
ACAGCUUTT) [47], and negative control siRNA
(siN05815122147) were purchased from RiboBio
(Guangzhou, China). The siRNA oligonucleotides
were transfected into NB4 cells using the Neon®
Transfection System (Invitrogen) following the manufac-
turer’s protocol [48].
Cell proliferation assays
Cell proliferation was quantified daily on days 0–4 with
the CCK-8 kit (Dojindo, Japan) according to the manu-
facturer’s protocol. NB4 cells were plated at a density of
1 × 104 cells/well in 96-well plates and cultured in RPMI
1640 medium containing 10 % FBS. The CCK-8 reagent
(10 μL) was added to the wells at the end of the experi-
ment. After incubation at 37 °C for 4 h, the absorbance
in each well was determined using a microplate reader
at 450 nm.
Additional file
Additional file 1: Figure S1. PVT1 expression in NB4-R2 cells treated
with ATRA. NB4-R2 cells were cultured in RPMI 1640 supplemented with
10 % FBS in the presence and absence of 1 μM ATRA for the indicated
time points. Total RNA was extracted, and PVT1 levels were determined
by qPCR. (DOCX 51 kb)
Abbreviations
APL: acute promyelocytic leukemia; ATRA: all-trans retinoic acid; lncRNA: long
non-coding RNA; qRT-PCR: quantitative reverse transcription-PCR;
siRNA: small interfering RNA.
Table 1 APL patient characteristics
APL primary (N = 28) Characteristics Median (range) No. (%)
Cytogenetics
t(15;17) 28 (100)





WBC count (×109/L) 22.93
Less than 10 10 (35.7)
10–50 9 (32.1)
50 or higher 2 (7.1)
N/A 7 (25)
Percent PB blasts 64.1
Below 80 % 10 (35.8)
80 % or above 9 (32.1)
N/A 9 (32.1)
WBC white blood cells, PB peripheral blood, N/A not available
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